Maxillofacial Plastic and Reconstructive Surgery

  • 제29권5호
  • /
  • Pages.456-462
  • /
  • 2007
  • /
  • 2288-8101(pISSN)
  • /
  • 2288-8586(eISSN)
대한악안면성형재건외과학회 (Korean Association of Maxillofacial Plastic and Reconstructive Surgeons)
권호 표지

Bisphosphonate, 구강악안면외과 영역의 새로운 위험 요소인가?

BISPHOSPHONATE, IS IT AN EMERGING RISK FACTOR IN ORAL SURGERY?

  • 권용대 (경희대학교 치과대학 구강악안면외과, 경희대학교 치과대학 구강생물학연구소) ;
  • 윤병욱 (경희대학교 치과대학 구강악안면외과, 경희대학교 치과대학 구강생물학연구소) ;
  • Kwon, Yong-Dae (Dept. of Oral & Maxillofacial Surgery, Kyung Hee University Dental School) ;
  • Yoon, Byung-Wook (Dept. of Oral & Maxillofacial Surgery, Kyung Hee University Dental School) ;
  • Walter, Christian (Dept. of Oral & Maxillofacial Surgery, University of Mainz)
  • 발행 : 2007.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Since the first description of bisphosphonate related osteonecrosis of the jaw (BRONJ) in 2002, the number of report on the disease has rapidly been increasing. Now, BRONJ is considered as a new entity, which is emerging problem in oral and maxillofacial surgery. Bisphosphonates (BPs) can be categorized into 2 groups: nitrogen-containing and non-nitrogen containing, and nitrogen-containing BPs are considered to have more efficacy and toxicity possibly. It is unusual for osteonecrosis to occur in the maxilla but BRONJ is found in both the mandible and the maxilla, which is one of the special features of BRONJ compared with common infectious osteomyelitis of the jaws. Intravenous BPs are usually more likely to cause BRONJ than oral BPs which are frequently prescribed for osteoporosis and osteopenia. Nonetheless, the use of intravenous BPs cannot be prevented because of systemic condition of the patients. Although it is rare that oral BPs cause BRONJ in osteoporosis/osteopenia patients, we should be aware of BRONJ since the population of the patients is exceedingly increasing with the prolonging of life expectancy. So, we'd like to enlighten upon the problems and solutions of BRONJ.

키워드

참고문헌

  1. Marx RE : Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws : a growing epidemic. J Oral Maxillofac Surg:61(9) : 1115, 2003 https://doi.org/10.1016/S0278-2391(03)00720-1
  2. Dimitrakopoulos I, Magopoulos C, Karakasis D : Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases. Int J Oral Maxillofac Surg 35(7) : 588, 2006 https://doi.org/10.1016/j.ijom.2006.02.022
  3. Ruggiero SL, Mehrotra B, Rosenberg TJ et al : Osteonecrosis of the jaws associated with the use of bisphosphonates : a review of 63 cases. J Oral Maxillofac Surg 62(5) : 527, 2004 https://doi.org/10.1016/j.joms.2004.02.004
  4. Bagan JV, Murillo J, Jimenez Y et al : Avascular jaw osteonecrosis in association with cancer chemotherapy : series of 10 cases. J Oral Pathol Med 34(2) : 120, 2005 https://doi.org/10.1111/j.1600-0714.2004.00269.x
  5. Ameican Association of Oral & Maxillofacial Surgeons : 2006 position paper on bisphosphonate-related osteonecrosis of the jaw. Available at http://www.aamos.org/, 2006
  6. Lin JH : Bisphosphonates : a review of their pharmacokinetic properties. Bone 18(2) : 75, 1996 https://doi.org/10.1016/8756-3282(95)00445-9
  7. Glowacki J : Bisphosphonates and bone. J at Harvard Med School 7 : 64, 2005
  8. van der Pluijm G, Vloedgraven H, van Beek E et al : Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98(3) : 698, 1996 https://doi.org/10.1172/JCI118841
  9. Haderslev KV, Tjellesen L, Sorensen HA et al : Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 119(3) : 639, 2000 https://doi.org/10.1053/gast.2000.16518
  10. National Osteoporosis Foundation : America's Bone Health. Available at http://nof.org/advocacy/prevalence/ index.htm
  11. Groetz KA : Zahnarztliche Betruung on Patienten mit tumortherapeutischer Kopf-Hals-Bestrahlung. Paper presented at : Deutsche Gesellschaft f?r Zahn-Mund- und Kieferheilkunde : Germany, 2003
  12. Hansen T, Kunkel M, Weber A et al : Osteonecrosis of the jaws in patients treated with bisphosphonates-histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35(3) : 155, 2006 https://doi.org/10.1111/j.1600-0714.2006.00391.x
  13. Altundag K, Bulut N, Tezcan E et al : Tooth extraction : Is it inciting event or sequela of osteonecrosis of the jaws associated with intravenous bisphosphonates? J Oral Maxillofac Surg 65(1) : 154, 2007
  14. Groetz KA, Al-Nawas B : Persisting alveolar sockets-a radiologic symptom of BP-ONJ? J Oral Maxillofac Surg 64(10) : 1571, 2006
  15. Zavras AI, Zhu S : Bisphosphonates are associated with increased risk for jaw surgery in medical claims data : is it osteonecrosis? J Oral Maxillofac Surg 64(6) : 917, 2006 https://doi.org/10.1016/j.joms.2006.02.011
  16. Bamias A, Kastritis E, Bamia C et al : Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23(34) : 8580, 2005 https://doi.org/10.1200/JCO.2005.02.8670
  17. Durie BG, Katz M, Crowley J : Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353(1) : 99 : discussion 99-02, 2005 https://doi.org/10.1056/NEJM200507073530120
  18. Dimopoulos MA, Kastritis E, Anagnostopoulos A et al : Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates : evidence of increased risk after treatment with zoledronic acid. Haematologica 91(7) : 968, 2006
  19. American Dental Association : Dental management of patients receiving oral bisphosphonate therapy : expert panel recommendations. J Am Dent Assoc 137(8) : 1144, 2006 https://doi.org/10.14219/jada.archive.2006.0355
  20. Black DM, Delmas PD, Eastell R et al : Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18) : 1809, 2007 https://doi.org/10.1056/NEJMoa067312
  21. Walter C, Grotz KA, Kunkel M : Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 15(2) : 197, 2007 https://doi.org/10.1007/s00520-006-0120-z
  22. Ficarra G, Beninati F, Rubino I et al : Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 32(11) : 1123, 2005 https://doi.org/10.1111/j.1600-051X.2005.00842.x
  23. American Association of Endodontists : Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws. In : http://www.aae.org/NR/rdonlyres/4CF5373C- 690A-40D8-A542-2346F1996B4A/0/bisphosonatesstatement. pdf, editor : American Association of Endodontists, 2006
  24. Ruggiero SL, Fantasia J, Carlson E : Bisphosphonaterelated osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102(4) : 433, 2006 https://doi.org/10.1016/j.tripleo.2006.06.004
  25. Bone HG, Hosking D, Devogelaer JP et al : Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350(12) : 1189, 2004 https://doi.org/10.1056/NEJMoa030897
  26. Rosen HN, Moses AC, Garber J et al : Serum CTX : a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66(2) : 100, 2000 https://doi.org/10.1007/PL00005830